Trial Profile
A randomised phase II/III multi-centre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Capecitabine; Cisplatin
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Acronyms SCOPE-1; SCOPE1
- 02 Aug 2019 Status changed from discontinued to completed.
- 14 Feb 2017 Final results of long term outcomes published in the British Journal of Cancer.
- 14 Nov 2014 United Kingdom Clinical Research Network reports accrual to date changed to 61%.